Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value
yahoo.com
finance
2022-10-18 13:25:00

Scopus BioPharma Inc.

Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated



Scopus BioPharma's Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million

Scopus Maintains Approximately 90% Ownership Stake in Duet

Duet Being Positioned to Go Public in 2023

NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: 'SCPS'), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today the completion of a series of related recapitalization transactions designed to enhance shareholder value.
